期刊
NATURE PROTOCOLS
卷 16, 期 2, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41596-020-00450-9
关键词
-
资金
- US NIH [U01 AI142756, RM1 HG009490, R35 GM118062]
- HHMI
- Helen Hay Whiteney post-doctoral fellowship
Genome editing technology, specifically base editing, holds great promise in treating genetic diseases with high efficiency and precision. Current base editors have shown high editing efficiencies in cell cultures and in vivo experiments, with new variants continuously being developed.
Genome editing has transformed the life sciences and has exciting prospects for use in treating genetic diseases. Our laboratory developed base editing to enable precise and efficient genome editing while minimizing undesired byproducts and toxicity associated with double-stranded DNA breaks. Adenine and cytosine base editors mediate targeted A center dot T-to-G center dot C or C center dot G-to-T center dot A base pair changes, respectively, which can theoretically address most human disease-associated single-nucleotide polymorphisms. Current base editors can achieve high editing efficiencies-for example, approaching 100% in cultured mammalian cells or 70% in adult mouse neurons in vivo. Since their initial description, a large set of base editor variants have been developed with different on-target and off-target editing characteristics. Here, we describe a protocol for using base editing in cultured mammalian cells. We provide guidelines for choosing target sites, appropriate base editor variants and delivery strategies to best suit a desired application. We further describe standard base-editing experiments in HEK293T cells, along with computational analysis of base-editing outcomes using CRISPResso2. Beginning with target DNA site selection, base-editing experiments in mammalian cells can typically be completed within 1-3 weeks and require only standard molecular biology techniques and readily available plasmid constructs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据